White Paper

Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness Using "Manufacturing By Design" Methodology

Source: Catalent
Cells

The ex-vivo Cell and Gene Therapy medicine field has entered into a new era driven by the registration of the first autologous products namely Kymriah (Novartis, 2017, US), Yescarta (Kite/Gilead, 2017, US) and Strimvelis (GSK/Orchard, 2016, Europe). Despite this very promising context, cell-based processes are far from being mature from an industrial perspective. One proof is the frequent news of quality issues (Out-of-Specification) on cell therapy products. The industry overall has a driving need to develop “next-generation” autologous processes with the objective of improving manufacturability (process length, automation et. al.) and to become increasingly commercially competitive.

Following closely behind the recent success of autologous cellular therapies, allogeneic T-cell therapies are moving toward late-stage clinical trials and commercial registration with the promise of having these breakthrough therapies available for market launch. Consequently, a new race to market has begun among “allogeneic CAR-T pioneers” (e.g. Servier, Cellectis, Allogene, Crispr Therapeutics, Precision Bioscience et. al.).

Cell and Gene Therapy companies need to invest time, effort and funds to improve process manufacturability as it will be the key for long-term commercial success.

T-Cell-based products can be classified as non-traditional therapeutic products in the biotechnology industry and rely on complex and challenging process optimization and manufacturing. The most common traits of both allogeneic and autologous processes are:

High variability due to the nature of the starting material (e.g. variety of cell types, living biological organisms). Non-industrial equipment that is often only partially compatible with current GMP standards

Process scale with process volume ranging from a few millimeters to a few liters

Aseptic processing with no possibility to perform sterile filtration

Economy of scale that is especially challenging for autologous production processes

Contract development and manufacturing organizations need to play a critical role in the scale-up and industrialization of cellular therapies by providing customized tools and processes. The Manufacturing by Design approach for addressing the industrialization of cell therapies allows for optimal production conditions.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: